首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1623304

腫瘤壞死因子（TNF）抑制劑的全球市場規模：按藥物類型、應用、分銷管道、地區、範圍和預測

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Size By Drug Type, By Application (Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis, Crohn's Disease), By Distribution Channel, By Geographic Scope and Forecast

出版日期: 2024年10月19日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

腫瘤壞死因子（TNF）抑制劑的市場規模及預測

2024年腫瘤壞死因子（TNF）抑制劑市場規模為2,488億美元，2024年至2031年複合年增長率為64.00%，預計2031年將達131,965億美元。TNF 抑制劑是抑制發炎細胞激素 TNF-a 的藥物，TNF-a 參與全身性發炎和免疫反應。TNF-α是自體免疫疾病和發炎性疾病（例如類風濕性關節炎、牛皮癬、克隆氏症和僵直性脊椎炎）發展的主要因素。這些藥物可阻斷 TNF-a、減輕發炎、緩解症狀並減緩疾病進展。

抑制腫瘤壞死因子（TNF）的藥物徹底改變了各種發炎和自體免疫疾病的治療。這些藥物透過標靶和中和 TNFα 發揮作用，TNFα 是一種參與各種慢性疾病發展的發炎細胞因子。TNF抑制劑主要用於治療類風濕性關節炎。類風濕性關節炎是一種慢性自體免疫疾病，會引起發炎和關節退化。

腫瘤壞死因子 (TNF) 抑制劑的未來用途預計將呈指數級增長，因為正在進行的研究揭示了它們治療比目前用途更廣泛的疾病的潛力。傳統上，TNF 抑制劑透過靶向和中和 TNFα（一種與這些疾病有關的發炎細胞因子）來治療自體免疫疾病，例如類風濕性關節炎、克隆氏症和牛皮癬。

腫瘤壞死因子（TNF）抑制劑的全球市場動態

主要市場推動因素

自體免疫疾病增加

類風濕性關節炎、克隆氏症和牛皮癬等自體免疫疾病的盛行率不斷上升，推動了對 TNF 抑制劑的需求。根據世界衛生組織 (WHO) 統計，全球自體免疫疾病呈上升趨勢，光是類風濕性關節炎就佔人口的 1%。

生物技術的進步

最近的生物技術趨勢大大提高了 TNF 抑制劑的開發和功效。配方的改進和生物相似藥的引入增加了治療選擇，並使 TNF 抑制劑更實惠。例如，生物相似藥的開發降低了治療成本，同時增加了市場競爭，導致TNF抑制劑市場的成長。

改進的識別和診斷：

對自體免疫疾病的瞭解和早期檢測的提高導致對 TNF 抑制劑的需求不斷增長。隨著認識活動和診斷工具的改進，越來越多的人被診斷出患有 TNF 抑制有效的疾病。根據美國風濕病學會的說法，早期準確的診斷可以更好地管理慢性病，並強調 TNF 抑制劑等有效藥物的重要性。

主要課題

感染風險：

TNF 抑制劑會削弱免疫系統，讓您更容易受到感染。服用這些藥物的患者更容易受到嚴重感染，如結核病、真菌感染和機會性病原體。治療前監測和潛伏性結核病篩檢等預防措施很重要，但使患者護理和治療依從性變得複雜。

成本高：

TNF 抑制劑是最昂貴的藥物之一。這些藥物的高昂成本可能會限制患者的使用，尤其是那些沒有完全享受保險的患者。這些經濟負擔也給醫療保健系統帶來壓力，並可能導致不同地區和人群在獲得治療方面存在差異。

長期安全問題

TNF 抑制劑的長期安全性仍令人擔憂。長期使用 TNF 抑制劑會增加罹患癌症和自體免疫疾病的風險。需要進行縱向研究來進一步瞭解這些風險並確定減少潛在負面影響的技術。

主要趨勢

採用生物相似藥

一個值得注意的趨勢是 TNF 抑制劑生物相似藥的使用不斷增加。生物相似藥是一種與原廠生物產品幾乎相同的克隆，並提供更便宜的選擇。隨著英夫利西單抗和依那西普等主要 TNF 抑制劑的專利到期，生物相似藥由於節省成本以及類似的功效和安全性而越來越受歡迎。

擴展到新的適應症

TNF 抑制劑正被用於新的和以前未知的應用。這一增長反映了旨在擴大 TNF 抑制劑治療用途的持續研究和臨床研究，這可能為患有各種發炎性疾病的患者帶來新的市場機會和更好的治療選擇。

新型TNF抑制劑的開發：

業界正在推出具有更好性能的新型 TNF 抑制劑。藥物開發商正在努力開發下一代 TNF 抑制劑，以提高療效、減少副作用並提高患者依從性。具有更具體作用機轉和增強劑量方案的藥物就是創新的例子。

Tumor Necrosis Factor TNF Inhibitor Drugs Market size was valued at USD 248.8 Billion in 2024 and is projected to reach USD 13019.65 Billion by 2031, growing at a CAGR of 64.00% from 2024 to 2031. TNF inhibitors are medications that suppress the pro-inflammatory cytokine TNF-a which plays a role in systemic inflammation and immunological response. TNF-a is a key factor in the development of autoimmune and inflammatory disorders like rheumatoid arthritis, psoriasis, Crohn's disease, and ankylosing spondylitis. These medications block TNF-a, reducing inflammation, alleviating symptoms, and slowing the evolution of diseases.

Drugs that block tumor necrosis factor (TNF) have transformed the treatment of a variety of inflammatory and autoimmune disorders. These medications function by targeting and neutralizing TNF-alpha, a pro-inflammatory cytokine involved in the development of various chronic diseases. TNF inhibitors are primarily used to treat rheumatoid arthritis. RA is a chronic autoimmune illness that causes inflammation and joint degeneration.

The future use of Tumor Necrosis Factor (TNF) inhibitor medications is expected to grow dramatically as ongoing research reveals their potential in treating a larger spectrum of illnesses than their current uses. TNF inhibitors have traditionally been used to treat autoimmune disorders such as rheumatoid arthritis, Crohn's disease, and psoriasis by targeting and neutralizing TNF-alpha, a pro-inflammatory cytokine implicated in these conditions.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Dynamics

The key market dynamics that are shaping the global tumor necrosis factor TNF inhibitor drugs market include:

Key Market Drivers:

Rising Incidence of Autoimmune Diseases

: The rising prevalence of autoimmune disorders such as rheumatoid arthritis, Crohn's disease, and psoriasis is driving demand for TNF inhibitor medications. According to the World Health Organization (WHO), autoimmune disorders are on the rise worldwide with rheumatoid arthritis alone accounting for an estimated 1% of the population.

Advancements in Biotechnology:

Recent advances in biotechnology have considerably improved the development and efficacy of TNF inhibitors. Improved medication formulations and the introduction of biosimilars are increasing therapy options and making TNF inhibitors more affordable. For example, the development of biosimilars has reduced treatment costs while increasing market competition resulting in growth in the TNF inhibitor market.

Increased Awareness and Diagnosis:

Better understanding and early detection of autoimmune disorders contribute to the increased need for TNF inhibitors. As awareness campaigns and diagnostic tools advance, more people are being diagnosed with illnesses that can benefit from TNF inhibition. According to the American College of Rheumatology, early and precise diagnosis leads to better management of chronic diseases emphasizing the importance of effective medications such as TNF inhibitors.

Key Challenges:

Infection Risk:

TNF inhibitors can depress the immune system making it more susceptible to infection. Patients using these drugs are more susceptible to serious infections such as tuberculosis, fungal infections, and opportunistic pathogens. Monitoring and preventive measures such as screening for latent tuberculosis before beginning treatment are critical but they also complicate patient care and therapy adherence.

High Cost:

TNF inhibitors are some of the most expensive drugs available. The high cost of these drugs may limit access for patients, particularly those without complete insurance coverage. This financial burden can also put a strain on healthcare systems leading to discrepancies in treatment availability between areas and populations.

Long-Term Safety Concerns

: TNF inhibitors' long-term safety remains a source of concern. Prolonged use of these medicines has been linked to an increased risk of cancer and autoimmune diseases. Long-term research is still required to further understand these dangers and identify techniques for reducing potential negative consequences.

Key Trends:

Biosimilar Adoption

: One notable trend is the increasing use of TNF inhibitor biosimilars. Biosimilars are virtually identical clones of branded biological medications that provide a more affordable option. With the patents for key TNF inhibitors such as infliximab and etanercept expiring, biosimilars have gained popularity due to their reduced cost and similar efficacy and safety profile.

Expansion into New Indications

: TNF inhibitors are being used in new ways that are not previously known. This increase reflects continuing research and clinical studies targeted at expanding the therapeutic applications of TNF inhibitors which could lead to new market opportunities and better treatment options for patients suffering from a variety of inflammatory disorders.

Development of Novel TNF Inhibitors:

The industry is seeing the introduction of novel TNF inhibitors with enhanced characteristics. Drug developers are working on next-generation TNF inhibitors with increased efficacy, fewer side effects, and greater patient compliance. Drugs with more specific modes of action and enhanced dosing regimens are examples of innovations.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global tumor necrosis factor TNF inhibitor drugs market:

North America:

In North America, the tumor necrosis factor (TNF) inhibitor medicines market is primarily driven by the rising prevalence of autoimmune illnesses and increased investment in healthcare infrastructure. Autoimmune disorders like rheumatoid arthritis, Crohn's disease, and psoriasis are growing more widespread creating a greater need for effective therapies. According to the Centers for Disease Control and Prevention (CDC), roughly 54.4 million persons in the United States have arthritis including rheumatoid arthritis which considerably increases the need for TNF inhibitors.

Significant investment in healthcare infrastructure and research in North America fuels the growth of the TNF inhibitor market. The National Institutes of Health (NIH) announced a significant increase in funding for research on autoimmune illnesses and innovative therapeutic medicines including TNF inhibitors. In 2023, the NIH will devote nearly USD 1.4 Billion to autoimmune disease and inflammatory research underscoring the region's commitment to developing therapeutic choices and improving patient outcomes. This strong financial backing enables the discovery and availability of novel TNF inhibitors, hence promoting market growth.

Asia Pacific:

The tumor necrosis factor (TNF) inhibitor pharmaceuticals market is expanding rapidly in Asia Pacific owing to several causes. The rising prevalence of autoimmune illnesses in the region is the market's fastest-growing driver. According to the World Health Organization (WHO), autoimmune disorders such as rheumatoid arthritis and Crohn's disease are on the rise worldwide with a significant increase in Asia. This increased incidence immediately increases the demand for TNF inhibitors which are important in controlling these disorders since they target the inflammatory mechanisms that cause autoimmune diseases.

Another key driver for the TNF inhibitor market in the Asia Pacific is the expansion of healthcare infrastructure and improved access to innovative treatments. The region has experienced significant investment in healthcare infrastructure, particularly in growing nations such as India and China. This growth of healthcare infrastructure improves the availability and accessibility of TNF inhibitors allowing more patients to benefit from these sophisticated medicines. Furthermore, government initiatives and regulations aiming at improving healthcare access and affordability are driving the industry.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market: Segmentation Analysis

The Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is segmented based on Drug Type, Application, Distribution Channel and Geography.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Drug Type

Monoclonal Antibodies
Soluble TNF Receptor
Biosimilars

Based on the Drug Type, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is bifurcated into Monoclonal Antibodies, Soluble TNF Receptor, and Biosimilars. Monoclonal antibodies are the dominant drug type in the global tumor necrosis factor (TNF) inhibitor drugs market. This dominance is due to their proven efficacy and established clinical track record in treating autoimmune diseases such as rheumatoid arthritis and Crohn's disease. Monoclonal antibodies like infliximab and adalimumab, specifically target TNF-alpha, a key driver of inflammation in these conditions offering significant therapeutic benefits and high patient response rates.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Application

Rheumatoid Arthritis (RA)
Psoriasis and Psoriatic Arthritis (PsA)
Crohn's Disease
Ankylosing Spondylitis
Other

Based on the Application, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is bifurcated into Rheumatoid Arthritis (RA), Psoriasis and Psoriatic Arthritis (PsA), Crohn's Disease, Ankylosing Spondylitis, Others. In the global tumor necrosis factor (TNF) inhibitor drugs market, Rheumatoid Arthritis (RA) is the dominant application. RA's dominance is due to its high prevalence and the severe impact it has on patients' quality of life. The Arthritis Foundation reports that RA affects approximately 1% of the global population leading to significant healthcare costs and treatment needs. TNF inhibitors are highly effective in managing RA symptoms and slowing disease progression making them a crucial part of RA treatment regimens.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies & Drug Stores
Online Pharmacies

Based on the Distribution Channel, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is bifurcated into Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies. Hospital pharmacies are the dominant distribution channel in the tumor necrosis factor (TNF) inhibitor drugs market. This dominance is primarily due to the specialized nature of TNF inhibitors which are often prescribed for complex autoimmune conditions like rheumatoid arthritis and Crohn's disease. Hospital pharmacies are equipped to handle the specific storage, handling, and administration requirements of these drugs ensuring proper management and monitoring of patient responses.

Tumor Necrosis Factor TNF Inhibitor Drugs Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on Geography, the Global Tumor Necrosis Factor TNF Inhibitor Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is the dominant region in the global tumor necrosis factor (TNF) inhibitor drugs market. This dominance is primarily due to the region's advanced healthcare infrastructure, high prevalence of autoimmune diseases, and substantial investment in research and development. The U.S. and Canada have well-established healthcare systems and are early adopters of innovative treatments contributing to a high uptake of TNF inhibitors. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, approximately 1.5 million Americans suffer from rheumatoid arthritis highlighting the significant patient base for TNF inhibitors.

Key Players

The "Global Tumor Necrosis Factor TNF Inhibitor Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer, Merck & Co., Samsung Bioepis, Sanofi, and Boehringer Ingelheim.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Key Developments

In July 2022, Sandoz gained approval from the United States Food and Drug Administration (FDA) to examine its Supplemental Biologics License Application for a high-concentration formulation of 100 mg/mL (HCF) of its biosimilar Hyrimoz (adalimumab).
In February 2022, MyMD Pharmaceuticals Inc. presented Phase 1 clinical study findings indicating that MYMD-1 reduces tumor necrosis factor-alpha (TNF-a), a key driver of aging, in the blood of healthy individuals.